Recon: GSK, Pfizer RSV vaccine sales drop in the US; Sage abandons Alzheimer’s drug after late-stage trial miss

• Harris seeks to tie expanded Medicare drug price negotiation to home care policy (STAT)
• A pariah in science, the ‘CRISPR babies’ researcher gains support from a U.S. cryptocurrency entrepreneur (STAT)
• White House should declare national emergency over IV fluid shortages caused by Helene, says hospital group (STAT)
• Sage Therapeutics scraps Alzheimer’s drug development after trial fails; shares slide (Reuters)
• Q&A: Why the NIH is spending $30 million to counter ableism in health care (STAT)
• Compounding group sues FDA for removing Lilly’s obesity drug from its shortages list (STAT)
• Pfizer's former top executives pitched changes to board as part of activist's plan (Endpoints)
• GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up (Reuters)
• GSK touts 3-year data on RSV shot Arexvy after CDC's narrower usage recommendation (Fierce Pharma)
• Danco to seek FDA nod for use of abortion drug in miscarriages, WSJ reports (Reuters)

• 12 people changing the course of the Chinese biopharma industry (STAT)
• Eversana sets up shop in Germany with newest pharma commercialization services outpost (Fierce Pharma)
• UK Gets Behind PIM Database Plan And Tools For Improved NHS Medtech Adoption (MedTech Insight)
• EU's MDCG Releases Corrective And Preventive Action Plan Guidance For Notified Bodies (MedTech Insight)
• UK’s Healthcare AI Gets A Boost From Regulatory Innovation Office (MedTech Insight)
• Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents (Reuters)
• Could US-Style Priority Review Vouchers Drive European Neglected Disease R&D? (Pink Sheet)
• EU Pharma Reform: What You Need to Know Now (Pink Sheet)
• India Tightens Oversight Of CROs With Mandatory Registration (Pink Sheet)
• EU Launches Safety Review Of Finasteride And Dutasteride Over Suicidal Thoughts And Behavior (Pink Sheet)

• Biotech veteran John Maraganore raises $135 million for his ‘next-generation RNAi’ startup (STAT)
• Exclusive: A small San Diego biotech wants to change how Parkinson’s disease is diagnosed (Endpoints)
• Biogen to seek approval for high-dose Spinraza after unveiling new data (Endpoints)
• John Maraganore's RNAi biotech City Therapeutics debuts with $135M Series A (Endpoints)
• Black Diamond cuts workforce, prioritizes lung cancer drug (Endpoints)
• Afton Scientific eyes $200M plant expansion, 200 new jobs in Virginia (Fierce Pharma)
• WeightWatchers to offer compounded version of Novo Nordisk's weight-loss drug (Reuters)
• ‘There Is No Silver Bullet’ – Sandoz’s Haruvi Talks US Shortages (Pink Sheet)

• Exact Sciences wins FDA approval for improved stool-based colon cancer test (STAT)
• Otsuka, Amalgam partner on Alzheimer’s care tech; Hello Heart joins Amwell’s telehealth network (STAT)
• 2024 Nobel Prize winners: Physics award goes to Hopfield, Hinton for machine learning discoveries (STAT)
• Biogen turns to telehealth company to boost its postpartum depression drug (STAT)

• Trump’s dangerous Covid-19 revisionism (STAT)
• FTC’s New Commissioner ‘Dismayed’ By Agency Overreach (MedTech Insight)